Equity method investments

6 Months Ended

Feb. 29, 2020

Equity Method Investments and Joint Ventures [Abstract]

Equity method investments

Equity method investments

Equity method investments as of February 29, 2020 and August 31, 2019, were as follows (in millions, except percentages):

	February 29, 2020			August 31, 2019
	Carrying value		Ownership percentage	Carrying value		Ownership percentage
AmerisourceBergen	$	5,206	28%	$	5,211	27%
Others	1,715		8% - 50%	1,640		8% - 50%
Total	$	6,921		$	6,851

AmerisourceBergen Corporation (“AmerisourceBergen”) investment

As of February 29, 2020 and August 31, 2019, the Company owned 56,854,867 AmerisourceBergen common shares, representing approximately 28% and 27%, respectively, of its outstanding common stock, based on the most recent share count publicly reported by AmerisourceBergen. The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings attributable to the Company’s investment being classified within the operating income of its Pharmaceutical Wholesale segment. Due to the timing and availability of financial information of AmerisourceBergen, the Company accounts for this equity method investment on a financial reporting lag of two months. Equity earnings from AmerisourceBergen are reported as a separate line in the Consolidated Condensed Statements of Earnings. The financial performance of AmerisourceBergen, including any charges which may arise relating to its ongoing opioid litigation, will impact the Company's results of operations.

The Level 1 fair market value of the Company’s equity investment in AmerisourceBergen common stock at February 29, 2020 was $4.8 billion. As of February 29, 2020, the Company’s investment in AmerisourceBergen carrying value exceeded its proportionate share of the net assets of AmerisourceBergen by $4.4 billion. This premium of $4.4 billion was recognized as part of the carrying value in the Company’s equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets.

Other investments

The Company’s other equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Company Limited, the Company’s pharmaceutical wholesale investments in China; its investment in Sinopharm Medicine Holding Guoda Drugstores Co., Ltd., the Company's retail pharmacy investment in China, the Company's investment in BioScrip (resulting from its merger with Option Care Inc.), PharMerica Corporation and Shields Health Solutions in the United States.

The Company reported $15 million and $9 million of post-tax equity earnings from other equity method investments, including equity method investments classified as operating, for the three months ended February 29, 2020 and February 28, 2019, respectively. The Company reported $7 million and $24 million of post-tax equity earnings from other equity method investments, including equity method investments classified as operating, for the six months ended February 29, 2020 and February 28, 2019, respectively.